The dopamine transporter is the primary means of inactivating synaptic dopamine as well as a major site of action for psychostimulants (such as cocaine and amphetamine) and for neurotoxins that induce parkinsonism. In the present study, a human dopamine transporter partial cDNA clone obtained by polymerase chain reaction exhibited 87% and 89% identity at the nucleic acid and amino acid levels, respectively, with transmembrane domains 3-5 of the rat homolog. This clone was used to quantitate human dopamine transporter mRNA by nuclease protection assay. The postmortem content of dopamine transporter mRNA in the substantia nigrae of 18-to 57-yr-old subjects was relatively constant, while in subjects >57 yr old, a precipitous (>95%) decline in substantia nigra dopamine transporter mRNA was evident. In contrast, tyrosine hydroxylase mRNA in the same samples declined in a linear manner with increasing age. In situ hybridization experiments confirmed the profound loss of dopamine transporter gene expression in melanin-positive (presumptive dopamine) nigral neurons. These data may begin to shed light on compensatory changes occurring in human dopamine neurons during normal aging.
The actions of many neurotransmitters are terminated by rapid reuptake into presynaptic nerve endings via neurotransmitter-specific, high-affinity, Na+-dependent membrane transporter proteins. The transporter for the neurotransmitter dopamine (DA) is apparently the receptor through which psychostimulants such as cocaine and amphetamine exert their potent reinforcing properties, leading to psychostimulant abuse and dependence (1) . In addition, the DA transporter mediates the active accumulation of neurotoxins such as 1-methyl-4-phenylpyridine into DA neurons (2, 3) , resulting in DA cell death and a parkinsonian syndrome. Thus, understanding the regulation of human DA transporter gene expression is an important step toward elucidation of the molecular bases of psychostimulant drug abuse and of neurotoxin-induced (and quite possibly idiopathic) parkinsonism.
Ligand binding to the human DA transporter decreases with age (4, 5) , in keeping with other evidence for an age-related loss of DA neurons (6) . Nevertheless, surprisingly little is known about the nature of normal age-related changes in human DA neurons, a process apparently distinct from the neuronal changes seen in Parkinson disease (6, 7) . In the present study, a human DA transporter cDNA clone was obtained by polymerase chain reaction, exploiting predicted sequence homology with the recently cloned, functionally related human norepinephrine transporter (8) . With the use of this clone, a precipitous, age-related loss of DA transporter mRNA was observed in human substantia nigra, while tyrosine hydroxylase mRNA, another phenotypic marker of DA neurons, decreased more linearly with age. These data may shed light on some compensatory changes occurring in human DA neurons during the normal aging process.
MATERIALS AND METHODS
Human substantia nigrae used for biochemical analyses (n = 36) were obtained at autopsy from the Wayne County Medical Examiner's Office, Sinai Hospital, or Wayne State University. Subjects (28 males, 8 females) ranged in age from 18 to 88 yr and died from a variety of causes, including, most commonly, heart attacks (n = 12), gunshot wounds (n = 7), or motor vehicle or other accidents (n = 5), with an average postmortem delay of 16.9 ± 1.3 hr. As described (9, 10), midbrain tissue blocks were transported on ice, and the substantia nigrae were dissected free according to the atlas of DeArmond et al. (11) , frozen on dry ice, and stored at -80°C until use.
RNA was extracted from tissues by the method of Chomczynski and Sacchi (12) . For the polymerase chain reaction, RNA was reverse transcribed with random hexamer primers, followed by a conventional polymerase chain reaction (94°C for 1.5 min, 55°C for 2 min, 72°C for 2 min; 25 cycles). Primers corresponded to human norepinephrine transporter cDNA sequences 509-534 (the 3' end of the third transmembrane domain) and 818-848 (the 5' end of the fifth transmembrane domain) and were constructed to have adjacent restriction endonuclease sites (sense primer, 5'-CTATAGGGAATTC-TCTACTACAACGTCATCATCGCCTGG-3'; antisense primer, 5'-ACTATAGTCTAGAACCACCTTTCCTGAT-GTCTTCACCCCTTTCC-3'; underlined sequences correspond to EcoRI and Xba I restriction sites, respectively). A prominent band of -360 base pairs visualized after gel electrophoresis was excised and reamplified by polymerase chain reaction. Using standard techniques (13), the reamplifled band was then digested with EcoRI and Xba I, ligated into pGEM-3Z plasmid, amplified in transformed Escherichia coli, and sequenced in both directions by the dideoxynucleotide chain-termination method. The cDNA clone obtained was designated HDAT1.O Human DA transporter mRNA was quantitated by using a variation of a previously described standard nuclease protection protocol (14) . HDAT1-derived 32P-labeled antisense RNA (200 pg) was used as a radioactive probe, while clonederived sense RNA (0-32 pg) was used as a standard. In pilot studies, equal (25 ,ug) amounts of substantia nigra RNA were analyzed for each subject, as illustrated in Fig. 2 1The sequence reported in this paper has been deposited in the GenBank data base (accession no. M96670).
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. analyses were conducted with 10-jIg RNA aliquots for subjects <58 yr old and 100-pug RNA aliquots for subjects >57 yr old. After overnight hybridization, samples were digested with S1 nuclease (500 units; 90 min at 370C) prior to polyacrylamide/urea gel electrophoresis, autoradiography, and densitometric quantitation. DA transporter mRNA values were expressed in terms of amol per pug of RNA as determined by linear regression fit of standards and pg-to-amol conversion. Subjects were divided into 10-yr epochs, beginning with the youngest subject obtained (18 yr old).
To assess the specificity of changes in DA transporter mRNA, 50-I&g samples of RNA from a number of subjects analyzed for DA transporter mRNA were also analyzed for tyrosine hydroxylase mRNA. Antisense RNA probe (100 pg) and sense RNA standards (0-80 pg) were derived from the human tyrosine hydroxylase clone phTH-63 (a generous gift of Karen O'Malley, Washington University). As reported (15) , the HTH-1 and HTH-2 forms of tyrosine hydroxylase mRNA were present in roughly equimolar amounts in human substantia nigra. HTH-2 mRNA was densitometrically quantitated (because of better electrophoretic separation from undigested probe) although HTH-1 content appeared to change in parallel (data not shown). For tyrosine hydroxylase mRNA, subjects were divided into 20-yr epochs because of the smaller number of subjects analyzed. Data are expressed as means ± SEM. Analysis of variance followed by planned comparison analyses (contrast analysis or linear trend analysis) was used to evaluate differences among groups.
For in situ hybridization analysis, midbrain tissue blocks from two male (42 and 60 yr old) subjects were stored at 4TC in 4% paraformaldehyde-containing 0.1 M sodium phosphate buffer (pH 7.4). One day before sectioning, tissue blocks were placed in 15% sucrose at 4eC overnight before mounting in Polyfreeze mounting medium (Polysciences), freezing on dry ice, and sectioning. Sections (20) (21) (22) (23) (24) (25) ,&m thick) were thaw-mounted on polylysine-coated slides and stored at -80TC until use. Representative sections from the two substantia nigrae were further processed in parallel essentially by the procedure of Kleinman et al. (16) . Briefly, sections were air-dried at room temperature, postfixed in 4% paraformaldehyde/0.1 M phosphate buffer, rinsed, and incubated for 30 min at 37TC with proteinase K (5 jug/ml). Unreacted aldehydes were quenched with 0.1 M glycine in 0.1 M phosphate/ 0.9%6 NaCl followed by 0.1 M triethanolamine (pH 8.0) containing 0.25% acetic anhydride. After rinsing and air drying, sections were preincubated with 100 1.d of hybridization buffer (16) hybridization buffer. Parafilm-covered sections were incubated for 18 hr at 550C. To verify the specificity of labeling, some sections were incubated with radiolabeled sense RNA probe. After incubation, sections were briefly rinsed and nonhybridized probe was digested with RNase A (20 units/ ml) (Sigma). Sections were washed at high stringency, dehydrated in graded ethanols containing 300 mM ammonium acetate, and air dried. After dipping in Kodak NTB3 nuclear emulsion at 1:1 dilution, slides were exposed for 10 days at -80'C, developed (with Kodak D19 developer), fixed, rinsed, and, in some cases, counterstained with cresyl violet. Each slide was then dehydrated through graded ethanols, cleared in xylene, and coverslipped with Permount. Sections were examined and photographed with a Zeiss photomicroscope III with standard bright-field optics and a dark-field condenser.
RESULTS
The cDNA clone HDAT1 was obtained by reverse transcription of human substantia nigra mRNA followed by polymerase chain reaction amplification with primers derived from the human norepinephrine transporter sequence. The HDAT1 nucleotide sequence exhibited 64% and 54% nucleic acid identity with the reported human norepinephrine and y-aminobutyric acid transporter cDNA sequences, respectively (8, 17) . HDAT1 showed 87% nucleic acid identity with the rat DA transporter cDNA sequences which were reported during the course of this study ( Fig. 1; refs. 18 and 19) . HDAT1 corresponds to the nucleotide sequence thought in the case of these other transporters to encode the 3' portion of transmembrane domain 3, the second extracellular loop with three or four N-glycosylation sites, transmembrane domain 4, the second intracellular loop, and the 5' portion of transmembrane domain 5. The predicted amino acid se- quence of the HDAT1 clone was 89% identical with the rat homolog, and three potential glycosylation sites within this sequence were identified (Fig. 1) . Nuclease protection assay with HDAT1-derived RNA probe detected a single RNA band of -330 nucleotides in human substantia nigra but not in numerous other human brain regions (cerebellum, cingulate cortex, hypothalamus, nucleus accumbens, putamen, or caudate; Fig. 2A) , consistent with the reported tissue distribution of rat DA transporter mRNA (18, 19) . Thus, on the basis of extensive homology with rat cDNA sequences and the pattern of tissue expression, it was concluded that HDAT1 encodes a portion of the human DA transporter. The relative abundance of human DA transporter mRNA in the substantia nigrae of some representative subjects of different ages is shown in Fig. 2B . The level of DA transporter expression in 18-to 57-yr-old subjects was relatively constant, while in subjects >57 yr old, a precipitous decline in substantia nigra DA transporter mRNA was evident (Fig.  2B) . Quantitative analysis was accomplished by comparison of samples with standard curves (as shown in Fig. 2A) , and by using 10-fold greater aliquots of RNA from subjects >57 yr old compared to younger subjects (see Materials and Methods). The individual DA transporter mRNA values obtained from 36 subjects are shown in Table 1 . These data are summarized in Fig. 3 . DA transporter mRNA content decreased significantly with age (F = 12.11; df = 5,30; P < 0.0001). Contrast analysis established that the 8-to 27-, 28-to 37-, 38-to 47-, and 48-to 57-yr-old groups did not differ from each other (P < 0.9116), but they did differ from the 58-to 67-and 68-to 88-yr-old groups, which exhibited a >95% loss of DA transporter mRNA (P < 0.0001; Fig. 3) .
In an effort to understand the relationship of this precipitous loss of DA transporter mRNA to the general status of DA neurons, aliquots of RNA from a number of the same subjects analyzed for DA transporter mRNA were also analyzed for the mRNA encoding tyrosine hydroxylase, the rate-limiting enzyme in DA biosynthesis. Individual values are again reported in Table 1 3 . Summary of age-related decline in human substantia nigra DA transporter mRNA. Columns represent means ± SEM. Numbers of subjects per group were as follows: 18-27 yr, 7; 28-37 yr, 6; 38-47 yr, 7; 48-57 yr, 4; 58-67 yr, 7; 68-88 yr, 5. Statistical analyses indicated that the first four groups (<58 yr old) did not differ from each other (P < 0.9116) but did significantly differ from the >57-yrold age groups (P < 0.0001). (Inset) Age-related change in human tyrosine hydroxylase (HTH) mRNA. RNA aliquots from some of the samples assayed for DA transporter mRNA were assayed for tyrosine hydroxylase mRNA. Numbers of subjects per group were as follows: 18-37 yr, 3; 38-57 yr, 7; 58-79 yr, 6. Statistical analyses indicated that there was an age-related decline in tyrosine hydroxylase mRNA (P < 0.0003) and that the decline was linear in nature (P < 0.0002).
DAT, DA transporter; TH, tyrosine hydroxylase. *amol per ,ug of RNA. tSamples shown in Fig. 2B .
Proc. Nati. Acad. Sci. USA 89 (1992) shown in Fig. 3 (Inset) . Substantia nigra tyrosine hydroxylase mRNA decreased significantly with age (F = 16.29; df = 2,13; P < 0.0003). Linear trend analysis verified that the decline in tyrosine hydroxylase mRNA was linear with increasing age (P < 0.0002; Fig. 3 Inset) .
Human DA transporter mRNA in the substantia nigrae of two subjects was visualized by in situ hybridization. An intense, heterogeneous labeling of DA transporter mRNApositive neurons was evident in midbrain sections from the younger (42 yr old) subject (Fig. 4a) . Fig. 4 b and c shows representative dark-field and bright-field photomicrographs, respectively, of a substantia nigra tissue section from this subject at a somewhat higher magnification. DA transporter mRNA was most often found associated with neuromelaninpositive (presumptive DA) neurons. No obvious correlation between the melanin content and the level of DA transporter mRNA within a given cell was observed. Occasional transporter-positive/melanin-negative or transporter-negative/ melanin-positive cells were also seen (data not shown). In contrast, in nigral tissue sections from the 60-yr-old subject, the vast majority of neuromelanin-positive cells did not express detectable levels of DA transporter mRNA ( (Figs. 2 and 3 ) demonstrating a precipitous agerelated loss of nigral human DA transporter mRNA.
DISCUSSION
In the experiments presented above, a human DA transporter cDNA was cloned ( Fig. 1 ) and used to characterize agerelated changes in DA transporter mRNA in the substantia nigrae of a large number of subjects postmortem. These analyses were feasible because of the significant postmortem stability of human brain mRNAs (10, 20, 21) . In fact, human DA transporter mRNA has previously been shown to be translationally active postmortem (9) . A striking (>95%) decrease in nigral DA transporter mRNA content was observed in subjects >57 yr old (Figs. 2 and 3) . The selective nature of the change in DA transporter mRNA levels is underscored by the nonparallel, linear decline in tyrosine hydroxylase mRNA levels in the same nigral RNA samples (Fig. 3 Inset) and by the direct visualization using in situ hybridization of decreased DA transporter mRNA in nigral neurons (Fig. 4) . Our working hypothesis is that the decreased DA transporter mRNA content reflects decreased transporter gene expression and results in decreased transporter protein levels. In fact, age-related (albeit smaller and more linear) decreases in DA transporter ligand binding in human putamen have been reported (4, 5) . In light of recent (22) , the true extent of age-related loss of DA transporter is likely to be greater than previously reported. Quantitation of DA transporter mRNA, protein, and ligand binding in the same subjects is necessary to address this question more directly.
The age-related decrease in human DA transporter mRNA seen in the present study could potentially arise by any number of mechanisms. It is conceivable that those DA cells expressing higher levels of the DA transporter are disproportionately lost during normal aging. This hypothesis is weakened somewhat by the remarkably constant DA transporter mRNA levels in subjects <58 yr old, the apparent absence of a significant subpopulation of transporter-negative DA cells in the 42-yr-old substantia nigra, and the precipitous decline in transporter mRNA that does occur in subjects >57 yr old. Nevertheless, if DA cell attrition during aging is, in fact, related to the level of transporter expression, a possible mechanism might involve accumulation of DA neurotoxins via the DA transporter. If this were the case, the distribution of midbrain DA cell loss due to transporter-accumulated toxin during aging might be expected to be similar to that seen in toxin-induced animal models of parkinsonism and perhaps even idiopathic Parkinson disease (23, 24) . In addition, the age-related vulnerability of DA neuron subpopulations should be correlated with the density of terminal DA transporters and/or cell body neuromelanin content, as has been suggested for Parkinson disease (25, 26) . To our knowledge, careful analyses of the distribution of human DA cell loss during normal aging have not been conducted.
It has been estimated that -40%o of human nigral DA neurons may be lost by age 60 as part of the normal aging process (6, 7) . The changes in tyrosine hydroxylase mRNA levels reported here (Fig. 3 Inset) are consistent with a DA cell loss of this magnitude (although age-or lesion-induced changes in DA cell number do not necessarily covary precisely with tyrosine hydroxylase mRNA or protein; refs. [27] [28] [29] . It is conceivable that as the loss of DA neurons reaches some critical level, the remaining DA cells may attempt to maintain synaptic DA levels in part by decreasing the amount of DA transporter available per DA nerve terminal. Compensatory mechanisms linked to DA cell loss in Parkinson disease and animal models of parkinsonism have been described (30) .
The implications of a substantial loss of human DA transporter gene expression during normal aging, if confirmed, are manifold. Individuals >57 yr old should be relatively resistant to the effects of DA transporter-accumulated neurotoxins. Interestingly, a large, multicenter study has reported that the mean age of onset of Parkinson disease is 57 yr, followed thereafter by a rapid age-related decline in the incidence of the disease (31) . Likewise, these individuals would be expected to exhibit a diminished responsiveness to drugs that normally interact with the DA transporter, such as the psychostimulants amphetamine, methylphenidate, and cocaine. In fact, the age-related loss of psychostimulant efficacy in individuals >60 yr old has been repeatedly documented (32) (33) (34) (35) (36) (37) . Clearly, further studies are necessary to elucidate the mechanism(s) underlying the age-related loss of human DA transporter mRNA, the relationship between transporter mRNA in the substantia nigra and DA transporter protein levels in DA nerve terminals, and the functional consequences of altered DA transporter gene expression for DA neurons and their target cells.
